Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22632665 | 0.91 | ALK (0.35) | L3MBTL1HTR6MAPTALDH1A1KDM4E | |
| SCHEMBL22632745 | 0.88 | L3MBTL1 (0.32) | L3MBTL1ALDH1A1TSHRALKPTPN11 | |
| SCHEMBL22638209 | 0.87 | PDE4A (0.35) | L3MBTL1ALDH1A1KLKB1GAATSHR | |
| SCHEMBL29414678 | 0.85 | PTGS2 (0.32) | L3MBTL1PTPN11HTT | |
| SCHEMBL22632642 | 0.85 | PTGS2 (0.32) | L3MBTL1PTPN11HTT | |
| SCHEMBL22632544 | 0.85 | ALK (0.36) | L3MBTL1HTR6MAPTALDH1A1KLKB1 | |
| SCHEMBL22632786 | 0.84 | CD4 (0.42) | L3MBTL1HTR6ALDH1A1ALK | |
| SCHEMBL22633321 | 0.84 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL31258414 | 0.84 | CD4 (0.42) | L3MBTL1HTR6ALDH1A1ALK | |
| SCHEMBL29414769 | 0.84 | L3MBTL1 (0.30) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4523692-A2 | MODULATORS OF THR-SS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3965884-B1 | MODULATORS OF THR-BETA WITH A DIOXO-1,2,4-TRIAZYL HEAD GROUP | ALIGOS THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | L3MBTL1 527/4885HTR6 710/4885MAPT 1399/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | L3MBTL1 1414/4885HTR6 945/4885MAPT 1383/4885 |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | L3MBTL1 527/4885HTR6 710/4885MAPT 1399/4885 |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | L3MBTL1 798/4885HTR6 765/4885MAPT 1243/4885 |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | L3MBTL1 798/4885HTR6 765/4885MAPT 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.